Skip to main content

Table 1 Demographics of the study population (control group vs haemoadsorption therapy)

From: Adsorption therapy in critically ill with septic shock and acute kidney injury: a retrospective and prospective cohort study

Characteristic Control group (n = 33) Haemoadsorption group (n = 43) p value
Age (years) 62 (53, 74) 63 (52, 71) NS
Sex female/male 4/29 12/31 NS
Weight (kg) 87 (78, 105) 90 (75, 100) NS
Septic focus NS
 Abdominal 9 13
 Catheter infection 0 1
 CNS 1 0
 Pulmonary 16 13
 Soft tissue 2 7
 Unclear 5 5
 Urinary tract 0 4
CRP before CVVHDF (mg/l) (n = 33 vs 42) 253 (173, 363) 250 (167, 337) NS
PCT before CVVHDF (ng/l) 7 (2, 30) 28 (11, 67) 0.002
IL-6 before CVVHDF (pg/ml) (n = 0 vs 41) Not measured 5000 (939, 5000)  
Noradrenaline before CVVHDF (µg/min) 44 (38, 62) 64 (48, 90) 0.005
Hydrocortisone administration 82% 81% NS
APACHE II before CVVHDF initiation 35 (33, 40) 39 (36, 42) 0.01
Lowest MAP 24 h before CVVHDF 65 (57, 73) 53 (40, 65) 0.03
Lowest GCS 24 h before CVVHDF (estimated if patient already sedated) 11 (3, 15) 3 (3, 3) NS
  1. CNS central nervous system, CRP C-reactive protein, PCT procalcitonin, IL-6 interleukins 6, CVVHDF continuous veno-venous haemodiafiltration, MAP middle arterial blood pressure, GCS Glasgow Coma Scale, NS not significant
\